Palisade Bio, Inc. (PALI) has disclosed a new risk, in the Employment / Personnel category.
Palisade Bio, Inc.’s potential to flourish hinges critically on its ability to attract and retain key personnel, particularly in senior management and scientific roles. The company faces a significant business risk as it operates without key person life insurance for executives and lacks employment agreements for many high-ranking staff members. The intense competition for skilled professionals in the pharmaceutical sector further exacerbates the challenge. Should Palisade Bio fail to secure and maintain such talent, the execution of its business strategy could be severely compromised, potentially derailing its operational timelines or broader objectives.
The average PALI stock price target is $1.50, implying 279.46% upside potential.
To learn more about Palisade Bio, Inc.’s risk factors, click here.
